Urinary early kidney injury molecules in children with beta-thalassemia major

References

• Hamed EA, ElMelegy NT. Renal functions in pediatric patients with beta-thalassemia major: Relation to chelation therapy: Original prospective study. Ital J Pediatr. 2010;25(2):36–39
   Google Scholar
• Quinn CT, Johnson VL, Kim HY, et al. Renal dysfunction in patients with thalassanemia: Thalassemia Clinical Research Network. Br J Hematol. 2011;153(1):111–117
   PubMed Web of Science ®Google Scholar
• Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353(11):1135–1146
   PubMed Web of Science ®Google Scholar
• Sumboonnanonda A, Malasit P, Tanphaichitr VS, et al. Renal tubular dysfunction in alphathalassemia. Pediatr Nephrol. 2003;18(3):257–260
   PubMed Web of Science ®Google Scholar
• Smolkin V, Halevy R, Levin C, et al. Renal function in children with beta-thalassanemia major and thalassanemia intermedia. Pediatr Nephrol. 2008;23(10):1847–1851
   PubMed Web of Science ®Google Scholar
• Economou M, Printza N, Teli A, et al. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta Hematol. 2010;123(3):148–152
   PubMed Web of Science ®Google Scholar
• Sadeghi-Bojd S, Hashemi M, Karimi M. Renal tubular function in patients with beta-thalassemia major in Zahedan, southeast Iran. Singapore Med J. 2008;49(5):410–412
   PubMed Web of Science ®Google Scholar
• Lai ME, Spiga A, Vacquer S, et al. Renal function in patients with β-thalassemia major: A long-term follow-up study. Nephrol Dial Transplant. 2012;27(9):3547–3551
   PubMed Web of Science ®Google Scholar
• Bhandari S, Galanello R. Renal aspects of thalassemia a changing paradigm. Eur J Hematol. 2012;89(3):187–197
   PubMed Web of Science ®Google Scholar
• Bagshaw SM, Gibney RT. Conventional markers of kidney function. Crit Care Med. 2008;36(4):152–158
   Web of Science ®Google Scholar
• Barrera-Chimal J, Bobadilla NA. Are recently reported biomarkers helpful for early and accurate diagnosis of acute kidney injury? Biomarkers. 2012;17(5):385–393
   PubMed Web of Science ®Google Scholar
• Devarajan P. Emerging urinary biomarkers in the diagnosis of acute kidney injury. Expert Opin Med Diagn. 2008;2(4):387–398
   PubMedGoogle Scholar
• Martensson J, Martling CR, Bell M. Novel biomarkers of acute kidney injury and failure: Clinical applicability. Br J Anaesth. 2012;109(6):843–850
   PubMed Web of Science ®Google Scholar
• Urbschat A, Obermüller N, Haferkamp A. Biomarkers of kidney injury. Biomarkers. 2011;16(1):22–30
   Google Scholar
• Negishi K, Noiri E, Doi K, et al. Monitoring of urinary L-type fatty acid-binding protein predicts histological severity of acute kidney injury. Am J Pathol. 2009;174(4):1154–1159
   PubMed Web of Science ®Google Scholar
• Naderi M, Sadeghi-Bojd S, Valeshabad AK, et al. A prospective study of tubular dysfunction in pediatric patients with Beta thalassemia major receiving deferasirox. Pediatr Hematol Oncol. 2013;30(8):748–754
   PubMed Web of Science ®Google Scholar
• Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629–637
   PubMed Web of Science ®Google Scholar
• Lanzkowsky P. Manual of Pediatric Hematology and Oncology. 4th ed. California: Elsevier; 2005
   Google Scholar
• Ponticelli C, Musallam KM, Cianciulli P, et al. Renal complications in transfusion-dependent beta thalassemia. Blood Rev. 2010;24(6):239–244
   PubMed Web of Science ®Google Scholar
• Ali BA, Mahmoud AM. Frequency of glomerular dysfunction in children with beta thalassemia major. Sultan Qaboos Univ Med J. 2014;14(1):88–94
   Google Scholar
• McCullough PA, Bouchard J, Waikar SS, et al. Implementation of novel biomarkers in the diagnosis, prognosis, and management of acute kidney injury: Executive summary from the tenth consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol. 2013;182(1):5–12
   PubMed Web of Science ®Google Scholar
• Aldudak B, Karabay Bayazit A, et al. Renal function in pediatric patients with beta thalassemia major. Pediatr Nephrol. 2000;15(1–2):109–112
   PubMed Web of Science ®Google Scholar
• Mohkam M, Shamsian BS, Gharib A, et al. Early markers of renal dysfunction in patients with beta thalassemia major. Pediatr Nephrol. 2008;23(6):971–976
   PubMed Web of Science ®Google Scholar
• Kassab-Chekir A, Laradi S, Ferchichi S, et al. Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. Clin Chim Acta. 2003;338(1–2):79–86
   PubMed Web of Science ®Google Scholar
• Naderi M, Sadeghi-Bojd S, Valeshabad AK, et al. A prospective study of tubular dysfunction in pediatric patients with Beta thalassemia major receiving deferasirox. Pediatr Hematol Oncol. 2013;30(8):748–754
   PubMed Web of Science ®Google Scholar
• Jalali A, Khalilian H, Ahmadzadeh A, et al. Renal function in transfusion-dependent pediatric beta-thalassemia major patients. Hematology. 2011;16(4):249–254
   PubMed Web of Science ®Google Scholar
• Fassett RG, Venuthurupalli SK, Gobe GC, et al. Biomarkers in chronic kidney disease: A review. Kidney Int. 2011;80(8):806–821
   PubMed Web of Science ®Google Scholar
• Goldstein SL, Devarajan P. Progression from acute kidney injury to chronic kidney disease: A pediatric perspective. Adv Chronic Kidney Dis. 2008;15(3):278–283
   PubMed Web of Science ®Google Scholar
• Nishida M, Kawakatsu H, Okumura Y, et al. Serum and urinary NGAL levels in children with chronic renal diseases. Pediatr Int. 2010;52(4):563–568
   PubMed Web of Science ®Google Scholar
• Sundaram N, Bennett M, Wilhelm J, et al. Biomarkers for early detection of sickle nephropathy. Am J Hematol. 2011;86(7):559–566
   PubMed Web of Science ®Google Scholar
• Kamijo A, Sugaya T, Hikawa A, et al. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem. 2006;284(1–2):175–182
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Kamijo-Ikemori A, Sugaya T, et al. Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage. Am J Pathol. 2009;174(6):2096–2106
   PubMed Web of Science ®Google Scholar
• Ferguson MA, Vaidya VS, Waikar SS, et al. Urinary liver-type fatty acid binding protein predicts adverse outcomes in acute kidney injury. Kidney Int. 2010;77(8):708–714
   PubMed Web of Science ®Google Scholar
• Chandra J, Chaudhary H, Pemde H, et al. Safety and efficacy of deferasirox in multitransfused Indian children with thalassemia major. Ann Trop Paediatr. 2011;31(1):47–51
   PubMed Web of Science ®Google Scholar
• Brosnahan G, Gokden N, Swaminathan S. Acute interstitial nephritis due to deferasirox: A case report. Nephrol Dial Transpl. 2008;23(10):3356–3358
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy and safety during 5 years’ follow-up. Blood. 2011;118(4):884–893
   PubMed Web of Science ®Google Scholar